2025
Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes
Zohora F, Nazari M, Sinusas A. Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes. Current Cardiology Reports 2025, 27: 61. PMID: 40009333, DOI: 10.1007/s11886-025-02197-9.Peer-Reviewed Original ResearchConceptsSudden cardiac deathImplantable cardioverter defibrillatorPositron emission tomographyImplantable cardioverter defibrillator placementMyocardial sympathetic denervationRisk stratificationSympathetic denervationIschemic heart diseaseHeart failurePrevention of sudden cardiac deathRisk stratification of patientsHeart diseaseOptimal risk stratificationLow ejection fractionStratification of patientsSympathetic nerve densityImprove risk stratificationHeart failure patientsPositron emission tomography radiotracersPredicting sudden cardiac deathPositron emission tomography tracersPrognostic benefitEjection fractionClinically practical approachNerve density[18F]MK-6240 Radioligand Delivery Indices as Surrogates of Cerebral Perfusion: Bias and Correlation Against [15O]Water.
Fu J, Juttukonda M, Garimella A, Salvatore A, Lois C, Ranasinghe A, Efthimiou N, Sari H, Aye W, Guehl N, El Fakhri G, Johnson K, Dickerson B, Izquierdo-Garcia D, Catana C, Price J. [18F]MK-6240 Radioligand Delivery Indices as Surrogates of Cerebral Perfusion: Bias and Correlation Against [15O]Water. Journal Of Nuclear Medicine 2025, 66: 410-417. PMID: 39947916, PMCID: PMC11876731, DOI: 10.2967/jnumed.124.268701.Peer-Reviewed Original ResearchCollagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis.
Ahmad A, Ghim M, Kukreja G, Neishabouri A, Zhang Z, Li J, Salarian M, Toczek J, Gona K, Hedayatyanfard K, Morrison T, Zhang J, Huang Y, Liu C, Yu S, Sadeghi M. Collagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis. Journal Of Nuclear Medicine 2025, 66: 425-433. PMID: 39915119, PMCID: PMC11876730, DOI: 10.2967/jnumed.124.268832.Peer-Reviewed Original ResearchConceptsPulmonary fibrosisTracer uptakeLung uptakeMurine model of pulmonary fibrosisModel of pulmonary fibrosisMice 3 wkEffect of antifibrotic therapyCollagen turnoverInterstitial lung diseaseClinical diagnostic methodsSPECT/CT imagingHybrid tracersLung histologyAntifibrotic therapyControl miceDisease activityMurine modelLung diseaseMice 8Tissue fibrosisPatient managementLiver uptakeSPECT/CTFibrosisSPECT imagesPET Imaging of Sphingosine-1-Phosphate Receptor 1 with [18F]TZ4877 in Nonhuman Primates
Gu J, Zheng M, Holden D, Fowles K, Qiu L, Felchner Z, Zhang L, Ropchan J, Gropler R, Carson R, Tu Z, Huang Y, Hillmer A. PET Imaging of Sphingosine-1-Phosphate Receptor 1 with [18F]TZ4877 in Nonhuman Primates. Molecular Imaging And Biology 2025, 27: 54-63. PMID: 39779653, DOI: 10.1007/s11307-024-01979-x.Peer-Reviewed Original ResearchConceptsSphingosine-1-phosphate receptor 1Absorbed radiation dose estimatesReceptor 1Nonhuman primatesFree fractionPlasma free fractionRadiation dose estimatesMetabolite-corrected input functionF-18 labeled radiotracersArterial blood samplesCritical organsPET/CT systemBolus injectionF-18Anesthetized nonhuman primatesDosimetry studiesHuman studiesDose estimatesVT/fPPET imaging dataS1PR1PET imagingInput functionBlood samplesPonesimodSelective Mu-Opioid Receptor Imaging Using 18F‑Labeled Carfentanils
Lee S, Pearson T, Dhaynaut M, MacDonagh A, Wey H, Wilks M, Roth B, Hooker J, Normandin M. Selective Mu-Opioid Receptor Imaging Using 18F‑Labeled Carfentanils. Journal Of Medicinal Chemistry 2025, 68: 1632-1644. PMID: 39772615, DOI: 10.1021/acs.jmedchem.4c02287.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrainFentanylFluorine RadioisotopesHumansMaleMicePositron-Emission TomographyRadiopharmaceuticalsRatsReceptors, Opioid, muTissue DistributionConceptsMu-opioid receptorsPositron emission tomographyIn vivo PET scansCarbon-11Neurobiological studiesCopper-mediated radiofluorinationMu-opioidReceptor imagingPET scansBrain uptakeFavorable pharmacokineticsImaging evaluationHigh molar activityMass doseEmission tomographyHalf-life of fluorine-18Synthetic opioidsFluorine-18Half-lifeIn vitro binding assaysBinding assaysClinical research useMolar activityCarfentanilResearch useIn Vivo Head-to-Head Comparison of [18F]GTP1 with [18F]MK-6240 and [18F]PI-2620 in Alzheimer Disease
Olafson E, Tonietto M, Klein G, Teng E, Stephens A, Russell D, Pickthorn K, Bohorquez S. In Vivo Head-to-Head Comparison of [18F]GTP1 with [18F]MK-6240 and [18F]PI-2620 in Alzheimer Disease. Journal Of Nuclear Medicine 2025, 66: jnumed.124.268623. PMID: 39746756, PMCID: PMC11800736, DOI: 10.2967/jnumed.124.268623.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseAccumulation of tau neurofibrillary tanglesTau neurofibrillary tanglesOff-target regionsNeurofibrillary tanglesTau pathologyTau-PET signalTau PET tracersBinding profilesTau-PETMild ADNormal cognitionBraak regionsHead-to-head studiesAD patientsTauMagnitude of uptakeTracer bindingAlzheimerTarget region
2024
Comparative Kidney Uptake of Nanobody-Based PET Tracers Labeled with Various Fluorine-18-Labeled Prosthetic Groups
Olkowski C, Basuli F, Fernandes B, Ghaemi B, Shi J, Zhang H, Farber J, Escorcia F, Choyke P, Jacobson O. Comparative Kidney Uptake of Nanobody-Based PET Tracers Labeled with Various Fluorine-18-Labeled Prosthetic Groups. Molecular Pharmaceutics 2024, 22: 533-543. PMID: 39680709, DOI: 10.1021/acs.molpharmaceut.4c01101.Peer-Reviewed Original ResearchPlasma Glial Fibrillary Acid Protein and Phosphorated Tau 181 Association with Presynaptic Density-Dependent Tau Pathology at 18F-SynVesT-1 Brain PET Imaging.
Wu J, Li B, Wang J, Huang Q, Chen X, You Z, He K, Guo Q, Li S, Huang Y, Guo T, Dai W, Xiang W, Chen W, Yang D, Zhao J, Guan Y, Xie F. Plasma Glial Fibrillary Acid Protein and Phosphorated Tau 181 Association with Presynaptic Density-Dependent Tau Pathology at 18F-SynVesT-1 Brain PET Imaging. Radiology 2024, 313: e233019. PMID: 39560478, PMCID: PMC11605102, DOI: 10.1148/radiol.233019.Peer-Reviewed Original ResearchConceptsP-tau-181Alzheimer's diseaseAD-related pathologyAmyloid-bPhosphor-tauTau pathologySynaptic densityTau accumulationSynaptic lossTauTau-PETDecreased synaptic densityGlial fibrillary acidic proteinPlasma glial fibrillary acidic proteinCortical thicknessAcidic proteinFibrillary acidic proteinRuijin HospitalProspective studyRelationship of plasmaBlood assayBlood markersPET/MRIBrain PET imagingPET imagingNeuroMark PET: Replicable positron emission tomography ICA templates for florbetapir and florbetaben radioligands
Eierud C, Fu Z, Petropoulos H, Bohsali A, Iraji A, Ganz M, Pernet C, Calhoun V. NeuroMark PET: Replicable positron emission tomography ICA templates for florbetapir and florbetaben radioligands. Annual International Conference Of The IEEE Engineering In Medicine And Biology Society (EMBC) 2024, 00: 1-4. PMID: 40039357, DOI: 10.1109/embc53108.2024.10782228.Peer-Reviewed Original ResearchMeSH KeywordsAgedAniline CompoundsBrainEthylene GlycolsFemaleHumansLigandsMalePositron-Emission TomographyRadiopharmaceuticalsStilbenesRevealing Alzheimer's Disease Dementia Patterns in [18F]Florbetapir PET with Independent Component Analysis
Khasayeva N, Eierud C, Jensen K, Premi E, Borroni B, Calhoun V, Iraji A. Revealing Alzheimer's Disease Dementia Patterns in [18F]Florbetapir PET with Independent Component Analysis. Annual International Conference Of The IEEE Engineering In Medicine And Biology Society (EMBC) 2024, 00: 1-4. PMID: 40039485, DOI: 10.1109/embc53108.2024.10782873.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlzheimer DiseaseAniline CompoundsBrainEthylene GlycolsFemaleHumansMalePositron-Emission TomographyRadiopharmaceuticalsConceptsPositron emission tomographyFrontal componentIndependent component analysisAlzheimer's Disease Neuroimaging InitiativeInteraction effects of diagnosisPositron emission tomography brain imagingEffect of diagnosisSignificant group effectAlzheimer's diseasePotential of independent component analysisAD dementia groupsSignificant interaction effectEvaluate group differencesGroup differencesDementia groupGeneralized linear modelGroup effectBrain imagingSalienceIC weightsEmission tomographyAD dementiaDementiaDementia patternsNeurobiologyAdvances and Insights in Positron Emission Tomography Tracers for Metabotropic Glutamate Receptor 4 Imaging
Wang J, Li Y, Fakhri G. Advances and Insights in Positron Emission Tomography Tracers for Metabotropic Glutamate Receptor 4 Imaging. Journal Of Medicinal Chemistry 2024, 67: 10517-10529. PMID: 38924702, PMCID: PMC11290609, DOI: 10.1021/acs.jmedchem.3c02431.Peer-Reviewed Original ResearchMeSH KeywordsAllosteric RegulationAnimalsBrainHumansLigandsPositron-Emission TomographyRadiopharmaceuticalsReceptors, Metabotropic GlutamateConceptsPositive allosteric modulatorsPositron emission tomographyPositron emission tomography radioligandsAllosteric modulatorsMGluR4 positive allosteric modulatorsMetabotropic glutamate receptor subtype 4PET ligandNeurological disordersPositron emission tomography tracersEmission tomographySubtype 4Molecular imaging modalitiesEffective treatmentMetabotropicDisordersParent drugImaging modalitiesPET tracersMGluR4Therapeutic targetPositron emitting radioisotopesSelection of lead compoundsLiving subjectsPositronQuantitative accuracyPET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [11C]MK-6884: Quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator
Belov V, Guehl N, Duvvuri S, Iredale P, Moon S, Dhaynaut M, Chakilam S, MacDonagh A, Rice P, Yokell D, Renger J, Fakhri G, Normandin M. PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [11C]MK-6884: Quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator. Cerebrovascular And Brain Metabolism Reviews 2024, 44: 1329-1342. PMID: 38477292, PMCID: PMC11342722, DOI: 10.1177/0271678x241238820.Peer-Reviewed Original ResearchConceptsPositive allosteric modulatorsReceptor occupancyNon-human primatesBinding potentialPositron emission tomographyMuscarinic acetylcholine receptorsAllosteric modulatorsNon-human primate brainM4 muscarinic acetylcholine receptorStriatal hyperdopaminergiaAcetylcholine receptorsBrain regionsCaudate nucleusTotal volume of distributionDose-dependent blockReference regionVolume of distributionPositron emission tomography imagingEmission tomographyReceptor levelsFunction of dosePET scansClinical trialsBlood-basedRhesus macaques
2023
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
Kurz S, Zan E, Cordova C, Troxel A, Barbaro M, Silverman J, Snuderl M, Zagzag D, Kondziolka D, Golfinos J, Chi A, Sulman E. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clinical Cancer Research 2023, 30: 680-686. PMID: 38048045, DOI: 10.1158/1078-0432.ccr-23-2533.Peer-Reviewed Original ResearchConceptsProgression-free survivalSomatostatin receptor type 2PFS-6Stable diseaseOverall survivalIntracranial meningiomasSingle-arm phase II clinical studyMedian progression-free survivalPhase II clinical studyImaging biomarkersCourse of radiationReceptor type 2Multicenter clinical trialMacdonald criteriaMedian OSRadiographic responseProgressive meningiomasTumor measurementsTumor resectionMedian agePrimary endpointRadiotherapeutic interventionSecondary endpointsMedical therapyAdult patientsEvaluation of a First PET Tracer Suitable for Imaging the Sigma‑2 Receptor in the Brain of Nonhuman Primates
Alluri S, Zheng M, Holden D, Zhang Y, Zhang L, Felchner Z, Li S, Ropchan J, Carson R, Jia H, Huang Y. Evaluation of a First PET Tracer Suitable for Imaging the Sigma‑2 Receptor in the Brain of Nonhuman Primates. Molecular Pharmaceutics 2023, 21: 194-200. PMID: 38013422, DOI: 10.1021/acs.molpharmaceut.3c00750.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrainMacaca mulattaNeoplasmsPositron-Emission TomographyPrimatesRadiopharmaceuticalsConceptsAlzheimer's diseaseLimited brain uptakeNonhuman primate brainCentral nervous systemPotential therapeutic targetPositron emission tomography (PET) imagingEmission Tomography ImagingTransmembrane protein 97Sigma-2 receptorsFirst PET tracerBrain penetrantBrain uptakeTherapeutic targetNervous systemPrimate brainNeurological disordersPET tracersNonhuman primatesTomography imagingProtein 97CancerDiseaseBrainCell typesReceptorsEvaluating infusion methods and simplified quantification of synaptic density in vivo with [11C]UCB-J and [18F]SynVesT-1 PET
Asch R, Naganawa M, Nabulsi N, Huan Y, Esterlis I, Carson R. Evaluating infusion methods and simplified quantification of synaptic density in vivo with [11C]UCB-J and [18F]SynVesT-1 PET. Cerebrovascular And Brain Metabolism Reviews 2023, 43: 2120-2129. PMID: 37669455, PMCID: PMC10925870, DOI: 10.1177/0271678x231200423.Peer-Reviewed Original ResearchThe historical progression of positron emission tomography research in neuroendocrinology
Bini J. The historical progression of positron emission tomography research in neuroendocrinology. Frontiers In Neuroendocrinology 2023, 70: 101081. PMID: 37423505, PMCID: PMC10530506, DOI: 10.1016/j.yfrne.2023.101081.Peer-Reviewed Original ResearchConceptsPositron emission tomographyPositron emission tomography researchEmission Tomography ImagingPositron emission tomography (PET) imagingNumber of radiopharmaceuticalsEndocrine organSystematic reviewEmission tomographyPET radioligandHormone actionTomography imagingPET imagingDifferent receptorsHuman brainPET researchImagingSystem actionsSteroidsCliniciansRadioligandHormoneBrainProgressionReceptorsPrevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases
Chan N, Einstein A, Griffin J, Rosenblum H, Teruya S, Cuomo M, De Los Santos J, DeLuca A, Johnson L, Kinkhabwala M, Leb J, Mintz A, Fine D, Helmke S, Muralidhar V, Pandey S, Sabogal N, Saith S, Winburn M, Smiley D, Miller E, Ruberg F, Maurer M. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. Journal Of Nuclear Cardiology 2023, 30: 2531-2539. PMID: 37311914, DOI: 10.1007/s12350-023-03310-7.Peer-Reviewed Original ResearchConceptsExtracardiac uptakePYP uptakeCardiac amyloidosisBone uptakeActionable findingsTiming of scansTransthyretin cardiac amyloidosisHeart failureBreast uptakeMean ageBlack raceRenal uptakeHispanic ethnicityThyroid uptakeATTR-CANuclear scintigraphyHispanic participantsTechnetium pyrophosphateNuclear imagingPYP scanPopulation studiesSelf-identified BlackAdditional testingAmyloidosisSubjectsBaseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study
Milgrom S, Kim J, Pei Q, Lee I, Hoppe B, Wu Y, Hodgson D, Kessel S, McCarten K, Roberts K, Lo A, Cole P, Kelly K, Cho S. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. British Journal Of Haematology 2023, 201: 1192-1199. PMID: 36922022, PMCID: PMC10247420, DOI: 10.1111/bjh.18734.Peer-Reviewed Original ResearchConceptsRapid early respondersEvent-free survivalTotal lesion glycolysisBaseline total lesion glycolysisIntensive therapyRisk stratificationTumor burdenHodgkin's lymphomaEarly respondersMTV/TLGFour-year event-free survivalBaseline metabolic tumor burdenExcellent event-free survivalHigh-risk Hodgkin lymphomaChildren's Oncology Group studyPoor event-free survivalMaximum standardized uptake valueResponse-adapted approachBaseline PET scanMetabolic tumor burdenStandardized uptake valueIntensified therapyLesion glycolysisBaseline PETTumor SUVFirst-in-Human PET Imaging of [18F]SDM-4MP3: A Cautionary Tale
Desmond K, Lindberg A, Garcia A, Tong J, Harkness M, Dobrota E, Smart K, Uribe C, Meyer J, Houle S, Strafella A, Li S, Huang Y, Vasdev N. First-in-Human PET Imaging of [18F]SDM-4MP3: A Cautionary Tale. Molecular Imaging 2023, 2023: 8826977. PMID: 37719326, PMCID: PMC10504053, DOI: 10.1155/2023/8826977.Peer-Reviewed Original ResearchDiagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study
Pandey S, Teruya S, Rodriguez C, Deluca A, Kinkhabwala M, Johnson L, Fine D, Sabogal N, Winburn M, Castillo M, Bhatia K, Malkovskaya R, Raiszadeh F, Kurian D, Miller E, Einstein A, Maurer M, Ruberg F. Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study. Journal Of Nuclear Cardiology 2023, 30: 1414-1419. PMID: 36823486, PMCID: PMC11268194, DOI: 10.1007/s12350-023-03203-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmyloidosisCardiomyopathiesDiphosphatesHumansPrealbuminRadiopharmaceuticalsTechnetiumTechnetium Tc 99m PyrophosphateConceptsTransthyretin cardiac amyloidosisATTR-CACardiac amyloidosisLow pretest probabilityLow pretest likelihoodLV wall thicknessDiagnostic performance characteristicsPositive predictive valueNon-invasive diagnosisConclusionAmong patientsMinority older adultsHeart failurePretest likelihoodPretest probabilitySemi-quantitative parametersPYP uptakeImportant misclassificationPredictive valueImaging thresholdsOptimal heartOlder adultsDiagnostic performancePatientsReference standardScans
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply